Editas Medicine Inc. (EDIT)

28.24
NASDAQ : Health Technology
Prev Close 27.97
Day Low/High 27.83 / 29.01
52 Wk Low/High 19.00 / 34.37
Avg Volume 885.50K
Exchange NASDAQ
Shares Outstanding 51.30M
Market Cap 1.43B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Buy Opportunities Dry Up as Stock Market 'Gaps and Slips'

Buy Opportunities Dry Up as Stock Market 'Gaps and Slips'

You have to be willing to chase if you want to establish new positions.

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.

KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers

KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers

Cambridge, Mass.-based KalVista Pharmaceuticals on Oct. 10 unveiled a collaboration pact with Merck.

Editas upgraded at Jefferies

M&A Could Ignite Next Leg Up for Biotech

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.